

**Antisense and RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, siRNA, miRNA, Antisense RNA), By Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Others), By Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032**

Market Report | 2024-05-06 | 0 pages | Straits Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Global Site License \$5500.00

**Report description:**

Antisense and RNAi Therapeutics Market Analysis and Insights

The Antisense and RNAi Therapeutics Market size is anticipated to reach USD 4.7 billion in 2023 and it is projected to reach USD 19.8 billion by 2032, growing at a CAGR of 17.4% during the forecast period.

The Global Antisense and RNAi Therapeutics Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Antisense and RNAi Therapeutics Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Experts, Antisense and RNAi Therapeutics Market includes major suppliers & Independent Consultants among others.  
Global Market Scope and Antisense and RNAi Therapeutics Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Antisense and RNAi Therapeutics Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Antisense and RNAi Therapeutics Market Country Level Analysis

The Global Antisense and RNAi Therapeutics Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Antisense and RNAi Therapeutics Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Antisense and RNAi Therapeutics Market

Some of the other major highlights of the demand for Antisense and RNAi Therapeutics Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Antisense and RNAi Therapeutics Market during the forecast period.

GSK plc

Olix Pharmaceuticals, Inc.

Sanofi

Alnylam Pharmaceuticals, Inc.

Arbutus Biopharma

Benitec Biopharma Inc.

Silence Therapeutics

Ionis Pharmaceuticals, Inc

Sarepta Therapeutics

Percheron Therapeutics Limited

Market Segmentation

The Global Antisense and RNAi Therapeutics Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Technology

RNA Interference

siRNA

miRNA

Antisense RNA

By Application

Oncology

Cardiovascular Diseases (CVDs)

Respiratory Disorders

Renal Diseases

Neurodegenerative Disorders

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Genetic Disorders  
Infectious Diseases  
Others

#### By Route of Administration

Intravenous Route  
Subcutaneous Route  
Intrathecal Route  
Pulmonary Delivery  
Intraperitoneal Injection  
Others

#### Regions Coverd

##### North America

U.S.  
Canada

##### Europe

U.K.  
Germany  
France  
Spain  
Italy  
Russia  
Nordic  
Benelux  
Rest of Europe

##### APAC

China  
Korea  
Japan  
India  
Australia  
Singapore  
Taiwan  
South East Asia

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Rest of Asia-Pacific

Middle East and Africa

UAE

Turkey

Saudi Arabia

South Africa

Egypt

Nigeria

Rest of MEA

LATAM

Brazil

Mexico

Argentina

Chile

Colombia

Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

### **Table of Contents:**

- 1 Executive Summary
- 2 Research Scope & Segmentation
  - 2.1 Research Objectives
  - 2.2 Limitations & Assumptions
  - 2.3 Market Scope & Segmentation
  - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
  - 3.1 Emerging Regions / Countries
  - 3.2 Emerging Companies
  - 3.3 Emerging Applications / End Use
- 4 Market Trends
  - 4.1 Drivers
  - 4.2 Market Warning Factors
  - 4.3 Latest Macro Economic Indicators

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.4 Geopolitical Impact
- 4.5 Technology Factors
- 5 Market Assessment
  - 5.1 Porters Five Forces Analysis
  - 5.2 Value Chain Analysis
- 6 Global Antisense and RNAi Therapeutics Market Size Analysis
  - 6.1 By Technology
    - 6.1.1 RNA Interference
    - 6.1.2 siRNA
    - 6.1.3 miRNA
    - 6.1.4 Antisense RNA
  - 6.2 By Application
    - 6.2.1 Oncology
    - 6.2.2 Cardiovascular Diseases (CVDs)
    - 6.2.3 Respiratory Disorders
    - 6.2.4 Renal Diseases
    - 6.2.5 Neurodegenerative Disorders
    - 6.2.6 Genetic Disorders
    - 6.2.7 Infectious Diseases
    - 6.2.8 Others
  - 6.3 By Route of Administration
    - 6.3.1 Intravenous Route
    - 6.3.2 Subcutaneous Route
    - 6.3.3 Intrathecal Route
    - 6.3.4 Pulmonary Delivery
    - 6.3.5 Intraperitoneal Injection
    - 6.3.6 Others
- 7 North America Market Analysis
  - 7.1 By Technology
    - 7.1.1 RNA Interference
    - 7.1.2 siRNA
    - 7.1.3 miRNA
    - 7.1.4 Antisense RNA
  - 7.2 By Application
    - 7.2.1 Oncology
    - 7.2.2 Cardiovascular Diseases (CVDs)
    - 7.2.3 Respiratory Disorders
    - 7.2.4 Renal Diseases
    - 7.2.5 Neurodegenerative Disorders
    - 7.2.6 Genetic Disorders
    - 7.2.7 Infectious Diseases
    - 7.2.8 Others
  - 7.3 By Route of Administration
    - 7.3.1 Intravenous Route
    - 7.3.2 Subcutaneous Route
    - 7.3.3 Intrathecal Route
    - 7.3.4 Pulmonary Delivery

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.3.5 Intraperitoneal Injection
- 7.3.6 Others
- 7.3 U.S.
- 7.4 Canada
- 8 Europe Market Analysis
  - 8.1 By Technology
    - 8.1.1 RNA Interference
    - 8.1.2 siRNA
    - 8.1.3 miRNA
    - 8.1.4 Antisense RNA
  - 8.2 By Application
    - 8.2.1 Oncology
    - 8.2.2 Cardiovascular Diseases (CVDs)
    - 8.2.3 Respiratory Disorders
    - 8.2.4 Renal Diseases
    - 8.2.5 Neurodegenerative Disorders
    - 8.2.6 Genetic Disorders
    - 8.2.7 Infectious Diseases
    - 8.2.8 Others
  - 8.3 By Route of Administration
    - 8.3.1 Intravenous Route
    - 8.3.2 Subcutaneous Route
    - 8.3.3 Intrathecal Route
    - 8.3.4 Pulmonary Delivery
    - 8.3.5 Intraperitoneal Injection
    - 8.3.6 Others
  - 8.3 U.K.
  - 8.4 Germany
  - 8.5 France
  - 8.6 Spain
  - 8.7 Italy
  - 8.8 Russia
  - 8.9 Nordic
  - 8.10 Benelux
  - 8.11 Rest of Europe
- 9 APAC Market Analysis
  - 9.1 By Technology
    - 9.1.1 RNA Interference
    - 9.1.2 siRNA
    - 9.1.3 miRNA
    - 9.1.4 Antisense RNA
  - 9.2 By Application
    - 9.2.1 Oncology
    - 9.2.2 Cardiovascular Diseases (CVDs)
    - 9.2.3 Respiratory Disorders
    - 9.2.4 Renal Diseases
    - 9.2.5 Neurodegenerative Disorders

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2.6 Genetic Disorders
- 9.2.7 Infectious Diseases
- 9.2.8 Others
- 9.3 By Route of Administration
  - 9.3.1 Intravenous Route
  - 9.3.2 Subcutaneous Route
  - 9.3.3 Intrathecal Route
  - 9.3.4 Pulmonary Delivery
  - 9.3.5 Intraperitoneal Injection
  - 9.3.6 Others
- 9.3 China
- 9.4 Korea
- 9.5 Japan
- 9.6 India
- 9.7 Australia
- 9.8 Singapore
- 9.9 Taiwan
- 9.10 South East Asia
- 9.11 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
  - 10.1 By Technology
    - 10.1.1 RNA Interference
    - 10.1.2 siRNA
    - 10.1.3 miRNA
    - 10.1.4 Antisense RNA
  - 10.2 By Application
    - 10.2.1 Oncology
    - 10.2.2 Cardiovascular Diseases (CVDs)
    - 10.2.3 Respiratory Disorders
    - 10.2.4 Renal Diseases
    - 10.2.5 Neurodegenerative Disorders
    - 10.2.6 Genetic Disorders
    - 10.2.7 Infectious Diseases
    - 10.2.8 Others
  - 10.3 By Route of Administration
    - 10.3.1 Intravenous Route
    - 10.3.2 Subcutaneous Route
    - 10.3.3 Intrathecal Route
    - 10.3.4 Pulmonary Delivery
    - 10.3.5 Intraperitoneal Injection
    - 10.3.6 Others
  - 10.3 UAE
  - 10.4 Turkey
  - 10.5 Saudi Arabia
  - 10.6 South Africa
  - 10.7 Egypt
  - 10.8 Nigeria

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.9 Rest of MEA
- 11 LATAM Market Analysis
  - 11.1 By Technology
    - 11.1.1 RNA Interference
    - 11.1.2 siRNA
    - 11.1.3 miRNA
    - 11.1.4 Antisense RNA
  - 11.2 By Application
    - 11.2.1 Oncology
    - 11.2.2 Cardiovascular Diseases (CVDs)
    - 11.2.3 Respiratory Disorders
    - 11.2.4 Renal Diseases
    - 11.2.5 Neurodegenerative Disorders
    - 11.2.6 Genetic Disorders
    - 11.2.7 Infectious Diseases
    - 11.2.8 Others
  - 11.3 By Route of Administration
    - 11.3.1 Intravenous Route
    - 11.3.2 Subcutaneous Route
    - 11.3.3 Intrathecal Route
    - 11.3.4 Pulmonary Delivery
    - 11.3.5 Intraperitoneal Injection
    - 11.3.6 Others
  - 11.3 Brazil
  - 11.4 Mexico
  - 11.5 Argentina
  - 11.6 Chile
  - 11.7 Colombia
  - 11.8 Rest of LATAM
- 12 Competitive Landscape
  - 12.1 Global Antisense and RNAi Therapeutics Market Share By Players
  - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
  - 13.1 American International Industries (GIGI)
    - 13.1.1 Overview
    - 13.1.2 Business Information
    - 13.1.3 Revenue
    - 13.1.4 ASP
    - 13.1.5 Swot Analysis
    - 13.1.6 Recent Developments
  - 13.2 Olix Pharmaceuticals, Inc.
  - 13.3 Sanofi
  - 13.4 Alnylam Pharmaceuticals, Inc.
  - 13.5 Arbutus Biopharma
  - 13.6 Benitec Biopharma Inc.
  - 13.7 Silence Therapeutics
  - 13.8 Ionis Pharmaceuticals, Inc

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.9 Sarepta Therapeutics
- 13.10 Percheron Therapeutics Limited
- 14 Research Methodology
  - 14.1 Research Data
    - 14.1.1 Secondary Data
      - 14.1.1.1 Major secondary sources
      - 14.1.1.2 Key data from secondary sources
    - 14.1.2 Primary Data
      - 14.1.2.1 Key data from primary sources
      - 14.1.2.2 Breakdown of primaries
    - 14.1.3 Secondary And Primary Research
      - 14.1.3.1 Key industry insights
  - 14.2 Market Size Estimation
    - 14.2.1 Bottom-Up Approach
    - 14.2.2 Top-Down Approach
    - 14.2.3 Market Projection
  - 14.3 Research Assumptions
    - 14.3.1 Assumptions
  - 14.4 Limitations
  - 14.5 Risk Assessment
- 15 Appendix
  - 15.1 Discussion Guide
  - 15.2 Customization Options
  - 15.3 Related Reports
- 16 Disclaimer

**Antisense and RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, siRNA, miRNA, Antisense RNA), By Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Others), By Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032**

Market Report | 2024-05-06 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Job title\*

Company Name\*

Address\*

Zip Code\*

EU Vat / Tax ID / NIP number\*

City\*

Country\*

Date

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com